---
schema_version: "secwatch.filing_event.v1"
accession: "0001199835-24-000220"
form_type: "8-K"
ticker: null
cik: "0001504239"
company_name: "Point of Care Nano-Technology, Inc."
filed_at: "2024-06-10T23:59:59+00:00"
generated_at: "2026-06-01T05:16:52.710078+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PCNT acquires EZ Saliva diagnostic assets, issues 66M shares; control shifts to Dr. Guirguis

## Summary
- Acquired substantially all assets of Point of Care Nano-Technology, LLC, including EZ Saliva test kit IP and $101,400 cash, for 66M restricted shares.
- Dr. Raouf Guirguis became director and Chief Scientific Officer; his group obtained ~48.4% of outstanding common stock.
- Nathan Keele joined board with ~26.5% stake; previous controller Nicholas DeVito surrendered super-majority preferred for 5M common shares, remains CEO.
- Entered exclusive perpetual license with Zeus Diagnostics for oral-fluid patents in N.America; $35K upfront plus 7.5% royalty.
- Company to focus on commercializing EZ Saliva products; financial statements of acquired business to be filed by amendment.

## SEC filing metadata
- accession: 0001199835-24-000220
- form_type: 8-K
- cik: 0001504239
- company_name: Point of Care Nano-Technology, Inc.
- filed_at: 2024-06-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 5.01, 1.1, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1504239/000119983524000220/0001199835-24-000220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1504239/000119983524000220/pcnt-8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001199835-24-000220
- JSON: https://secwatch.observer/filing/0001199835-24-000220.json
- Plain text: https://secwatch.observer/filing/0001199835-24-000220.txt

## Key facts
- M&A Transactions
  Point of Care Nano-Technology, Inc. completed an acquisition involving Point of Care Nano-Technology, LLC for 66,000,000 restricted shares of the Company’s common stock (closed 2024-05-20).
  - Action: acquisition
  - Counterparty: Point of Care Nano-Technology, LLC
  - Consideration: 66,000,000 restricted shares of the Company’s common stock
  - Closing: 2024-05-20
  source text: of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. In exchange for the Assets, the Company is issuing to Point and/or its designees 66,000,000 restricted shares of the Company’s common stock (the “Consideration Shares”). Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf
  evidence_url: https://www.sec.gov/Archives/edgar/data/1504239/000119983524000220/0001199835-24-000220-index.htm
- M&A Transactions
  Point of Care Nano-Technology, Inc. underwent a change of control involving Point of Care Nano-Technology, LLC for 66,000,000 restricted shares of the Company’s common stock (closed 2024-05-20).
  - Action: change of control
  - Counterparty: Point of Care Nano-Technology, LLC
  - Consideration: 66,000,000 restricted shares of the Company’s common stock
  - Closing: 2024-05-20
  source text: of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. In exchange for the Assets, the Company is issuing to Point and/or its designees 66,000,000 restricted shares of the Company’s common stock (the “Consideration Shares”). Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf
  evidence_url: https://www.sec.gov/Archives/edgar/data/1504239/000119983524000220/0001199835-24-000220-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.